MS Treatment Cladribine Provides Quality of Life Benefits and Improved Cognition Over 4-Year Period

After 4 years of treatment, those on cladribine demonstrated a correlation between sustained health-related quality of life, specifically physical and mental health, and cognition.:

Source: Neurology Read More

Previous PostInsights on Baseline Characteristics From Major Clinical Trials in Progressive Multiple Sclerosis: Robert J. Fox, MD
Next PostArtificial Intelligence, Myelin Repair, and Aging as Emerging Frontiers in MS Research: Bruce Bebo, PhD

MS Treatment Cladribine Provides Quality of Life Benefits and Improved Cognition Over 4-Year Period

Previous PostInsights on Baseline Characteristics From Major Clinical Trials in Progressive Multiple Sclerosis: Robert J. Fox, MD

Next PostArtificial Intelligence, Myelin Repair, and Aging as Emerging Frontiers in MS Research: Bruce Bebo, PhD

Related Posts

<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>

<![CDATA[TEMPO-4 Extension Analysis: Tavapadon Shows Levodopa-Sparing Potential in Parkinson Disease]]>

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

Categories